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ABSTRACT 
A series of 27 cinchona alkaloid derivatives (1f-w, 2a-e and 3a-d) were investigated for their 
cytotoxic and trypanocidal activities using seven different cancer cell lines (KB, HeLa, MCF-
7, A-549, Hep-G2, U-87 and HL-60), two normal cell lines (HDF and CHO) and bloodstream 
forms of Trypanosoma brucei brucei, respectively. Four compounds (1u, 1w, 2e and 3d) 
were identified with promising cytotoxic activity with 50% growth inhibition (GI50) values 
below 10 µM. Two (2e and 3d) of the four compounds also exhibited potent anti-
trypanosomal activity with GI50 values of 0.3-0.4 µM. All four active compounds represented 
derivatives modified at their C-9 hydroxy group. With respect to anti-proliferative activity 
and selectivity, 2e (epi-N-quinidyl-N’-bis(3,5-trifluoromethyl)phenylthiourea) proved to be 
the most promising derivative for both cancer cells and bloodstream forms of T. b. brucei. 
The cytotoxic activity of compounds 1u, 1w, 2e and 3d was attributed to their ability to 
induce apoptosis in cancer cells. The results demonstrate the potential of cinchona alkaloid 
derivatives as novel anti-cancer and anti-trypanosome drug candidates. 
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1 INTRODUCTION 
The bark of the cinchona tree (Cinchona sp.) contains many bioactive quinoline-type 
alkaloids. Among them, quinine is both the most important and best known alkaloid of this 
class of natural compounds. Historically, quinine was the sole cure for malaria for centuries 
until the introduction of the synthetic analogue chloroquine after World War II. Other major 
alkaloids found in the cinchona bark are the closely related compounds quinidine, cinchonine 
and cinchonidine, which together with quinine are collectively classified as ‘cinchona 
alkaloids’. 
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Apart from their utilization as anti-malaria agents, cinchona alkaloids are also deployed to 
treat intestinal parasites, arrhythmia and other heart conditions, nocturnal leg cramps, and 
fever, and are used as a bitter digestive aid.
[1,2]
 In addition, cinchona alkaloids have been 
reported to be inhibitors of the P-glycoprotein, a membrane transporter that is overexpressed 
on tumour cells and responsible for the process of efflux of chemotherapeutics. For example, 
cinchonine has been shown to improve the accumulation of doxorubicin in cancer cells.
[3]
 
Moreover, cinchonine and quinine were found to induce apoptosis in cancer cells and thus 
inhibit their proliferation.
[4,5]
 Furthermore, cinchona alkaloids have been reported to display 
trypanocidal activity against bloodstream forms of Trypanosoma brucei and T. congolense 
with 50% growth inhibition (GI50) values in the mid to low micromolar range.
[6]
 These 
flagellated protozoan parasites are the causative agents of sleeping sickness in humans and 
nagana disease in cattle, and are transmitted by the bite of infected tsetse flies. African 
trypanosomiasis is one of the most neglected tropical diseases and throughout history, it has 
severely repressed the economic and cultural development of central Africa.
[7]
 As the few 
currently available chemotherapies of sleeping sickness and nagana disease are 
unsatisfactory,
[8]
 new and effective drugs are needed for treatment of African 
trypanosomiasis. 
 
The previous findings that native cinchona alkaloids have anti-cancer and anti-
trypanosomal properties prompted us to investigate whether the cytotoxic and trypanocidal 
activities of this class of natural products can be improved by their modification. In this study 
we report the cytotoxic and trypanocidal activities of 27 cinchona alkaloid derivatives (Table 
1) of which 8 were commercially available (1f-h, 2a-e) and 19 were synthesised (1i-w, 3a-d) 
according to published methods.
[9-16]
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2 MATERIALS AND METHODS 
2.1 Reagents 
Unmodified cinchona alkaloids 1a-e and their hydrogenated analogues 1f-h and 1k were 
purchased from Buchler GmbH (Braunschweig, Germany) or Sigma-Aldrich (Poznan, 
Poland). 9-Amino-9-epi-cinchona derivatives 2a-d and the thiourea 2e were bought from 
AdvaChemLab (Poznan, Poland). All other reagents required for organic synthesis and 
toxicity assays were obtained from Sigma-Aldrich (Poznan, Poland and Gillingham, U.K., 
respectively) and Fluorochem (Hadfield, U.K.) and used as received. 
 
2.2 Chemistry 
NMR spectra were recorded at 295 K on a Bruker Ascend 400 MHz spectrometer, operating 
at frequencies of 400 MHz for 
1
H and 101 MHz for 
13
C. All shifts were referenced to the 
internal tetramethylsilane. Mass spectra were determined on a Bruker Impact HD instrument. 
IR spectra were recorded using KBr pellets on a Brucker FT-IR IFS-66/s spectrometer. 
Dihydrocupreines 1i-j, 10,11-didehydrocinchona alkaloids 1l-m, cinchotenine derivatives 
1n-p and deoxyhydroquinidine 1q were prepared as previously described.
[9-12]
 Quinine esters 
1r-s and 9-O-carbamates 1t-w were synthesised using general procedures.
[13,14]
 Quaternary 
ammonium salts 3a-c were prepared by reaction of quinine with 9-anthracenylmethyl 
chloride or appropriate benzyl halides as previously reported while the salt 3d was obtained 
following a previous published protocol.
[15,16]
 All compounds were properly characterized 
and their purity was >95%. 
 
2.3 Cells 
KB, HeLa, MCF-7, Hep-G2 and CHO cells were obtained from the European Collection of 
Cell Culture (ECACC) supplied by Sigma Aldrich (Poznan, Poland). A-549, U-87, HDF and 
HL-60 cells were purchased from the American Type Culture Collection (ATCC) through 
LGC Standards (Lomianki, Poland and Teddington, U.K., respectively). Bloodstream forms 
of T. b. brucei 427-221a were previously obtained from the Wellcome Centre for Molecular 
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Parasitology (Glasgow, U.K.). This subspecies is non-pathogenic to humans but 
morphological and biochemical indistinguishable from the human pathogenic subspecies T. b. 
gambiense and T. b. rhodesiense. 
 
2.4 Cell culture and in vitro toxicity assay 
2.4.1 Tumour and normal cells 
KB, Hep-G2 and U-87 cells were cultured in EMEM medium while HeLa cells were grown 
in RPMI 1640 medium, A-549 and CHO cells in F-12K medium, MCF-7 cells in DMEM 
medium, U-87 in EMEM medium and HDF cells in Fibroblasts Growth Medium. Each 
medium was supplemented with 10% foetal bovine serum, 1% L-glutamine and 1% 
penicillin/streptomycin solution (final concentrations 100 U/ml penicillin and 100 µg/ml 
streptomycin). All cultures were maintained at 37°C in a humidified atmosphere containing 
5% CO2. 
 
For determining the cytotoxic activity of test compounds, the protein-staining 
sulforhodamine B (SRB) assay and/or the tetrazolium reduction (MTT) assay were employed. 
Both assays have been assessed by the National Cancer Institute (USA) as suitable for in 
vitro anti-tumour screening.
[17]
 The SRB and the MTT assay estimate cell densities based on 
measurement of cellular protein content and activity of oxidoreductase enzymes, respectively. 
For the SRB assay, 100 µl of diluted cell suspension containing approximately 10
4
 cells was 
added to the wells of 96-well plates. After 24 h, when a partial monolayer had formed, the 
supernatant was aspirated and 100 µl medium containing test compounds at six different 
concentrations (0.1, 0.2, 1, 2, 10 and 20 µg/ml) was added to the cells. Stock solutions of test 
compounds were prepared in DMSO and the concentration of DMSO in the assay did not 
exceed 0.1% which was found to be nontoxic to the different cell lines. After incubation for 
72 h, 25 µl of 50% trichloroacetic acid was added to each well and the plates were incubated 
for 1 h at 4°C. Thereafter, the plates were washed with distilled water to remove traces of 
medium and air-dried. Then, the dried plates were stained with 100 µl 0.4% SRB (prepared in 
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1% acetic acid) for 30 min at room temperature. Unbound dye was removed by rapidly 
washing with 1% acetic acid and the plates were air-dried overnight. Finally, the protein-
bound dye was dissolved in 100 µl of 10 mM unbuffered Tris and the absorbance read at 490 
nm. 
 
For the MTT assay, 180 µl of suspended cells (2  104/mL) was pipetted into the wells of 
96-well plates. After 24 h incubation, 20 µl of test compounds was added (final 
concentrations of 0.1, 0.2, 1, 2, 10 and 20 µg/ml) and the plates were incubated for another 48 
h. Then, 10 µl of 5 mg/ml MTT solution was added to each well and the plates incubated for 
additional 3 h. The formed formazan crystals were dissolved in 100 µl 10% sodium dodecyl 
sulphate (SDS) solution and the absorbance measured at 545 nm. 
 
The concentration of a compound required to inhibit cell growth by 50% (half-maximal 
growth inhibition; GI50) compared to the control was calculated using GraphPad Prism 
software. 
 
2.4.2 Trypanosomes and HL-60 cells 
Bloodstream forms of the non-human pathogenic subspecies T. b. brucei (clone 427-221a
[18]
) 
and human myeloid leukaemia HL-60 cells
[19]
 were grown in Baltz medium
[20]
 supplemented 
with 16.7% heat-inactivated bovine serum at 37°C in a humidified atmosphere. Toxicity 
assays with trypanosomes and HL-60 cells were carried out as previously described
[6]
 with 
some modifications. In brief, cells were seeded in 96-well plates in a final volume of 200 µl 
of Baltz medium containing test compounds serially diluted tenfold from 100 µM down to 
100 pM and 1% DMSO. Wells just containing medium and 1% DMSO served as controls. 
The initial cell densities were 1 × 10
4
/ml for trypanosomes and 5 × 10
4
/ml for HL-60 cells. 
After 24 h incubation, 20 µl of a 0.5 mM resazurin solution prepared in sterile PBS was 
added and the cells were incubated for a further 48 h. Thereafter, the absorbance of wells was 
read at 570 nm (test wavelength) and 630 nm (reference wavelength). The GI50 value, i.e., the 
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concentration of a compound necessary to reduce the growth rate of cells by 50% compared 
to the control was determined by linear interpolation as described previously.
[21]
 The 
minimum inhibitory concentration (MIC) values, i.e. the concentration of the drug at which 
all trypanosomes and human cells were killed, was determined microscopically. 
 
2.5 Apoptosis Assay 
The induction of apoptosis by test compounds was determined with the Cell Death Detection 
ELISA
PLUS
 from Roche Diagnostics GmbH (Mannheim, Germany). This is an enzyme 
immunoassay for the determination of cytoplasmic histone-associated DNA fragments 
(mono- and oligonucleotides) after induced cell death. Cells (10
4
) were pipetted into wells of 
96-well plates and test compounds added at final concentrations of 0.1, 1 and 10 µg/ml. Cells 
incubated in the absence of test compounds served as negative controls. After 4 h incubation, 
cells were harvested by centrifugation of the plates for 10 min at 200  g. Supernatants were 
removed carefully and cell pellets re-suspended in 200 µl lysis buffer and incubated for 30 
min at room temperature. After centrifugation of the plates (10 min, 200  g), 20 µl of cell 
lysates were transferred in duplicate into wells of provided streptavidin-coated microplates. 
Then, 80 µl of the immunoreagent containing a mixture of anti-histone-biotin monoclonal 
antibody and anti-DNA-peroxidase monoclonal antibody was added to each well. The 
microplates were covered with a provided adhesive foil and incubated for 2 h at room 
temperature. Thereafter, the solution in the wells was removed by tapping the microplate. The 
wells were rinsed three times with incubation buffer and 100 µl of substrate (2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid, ABTS) was added to each well. After 10-20 min, 100 
µl of ABTS stop solution was pipetted to each well and the absorbance was read at 405 nm 
(test wavelength) and 490 nm (reference wavelength). The apoptotic index was calculated 
based on the enrichment of mono- and oligonucleosomes according to the following 
equation: 
 
apoptotic index = [{A405(sample) – A490(sample)}  {A405(negative control) – A490(negative control)}]. 
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3 RESULTS AND DISCUSSION 
3.1 Cytotoxicity of cinchona alkaloid derivatives 
The cytotoxic activities of unmodified (1a-e) and derivatized (1f-u, 1w, 2a-c, 2e, 3d) 
cinchona alkaloids were evaluated with six human tumour cell lines (KB: cervix carcinoma 
derived from HeLa cells
a
; HeLa: cervix carcinoma; MCF-7: breast cancer; A-549: lung 
cancer; Hep-G2: liver cancer; U-87, glioblastoma) and two normal cell lines (HDF: human 
dermal fibroblast; CHO: Chinese hamster ovary cells) using the SRB and/or the MTT assay. 
The unmodified cinchona alkaloids 1a-c were not very cytotoxic with GI50 (half-maximal 
growth inhibition) values ranging from 36.4 µM to 155 µM for tumour cells and from 111 
µM to 397 µM for normal cells (Table 2). Similar cytotoxicity values have been previously 
reported for quinine and KB cells (GI50 = 118 µM; our study 55.5 µM) and for cinchonine 
and HeLa cells (GI50 = 180 µM; our study 155 µM).
[4,5]
 Cinchona alkaloid molecules with an 
ethyl, an ethynyl or a carboxyl group (1f-p) instead of the vinyl group displayed similar 
cytotoxic activities as their unmodified counterparts (Table 2). This finding suggests the vinyl 
group to be non-essential to the cytotoxic action of cinchona alkaloids. On the other hand, 
some compounds with a modified C-9 hydroxy group showed improved cytotoxicities 
compared to the unmodified precursors. While compounds without a C-9 hydroxy group (1q) 
or with an esterified C-9 hydroxy group (1r-s) did not show increased cytotoxic activities, 
two 9-O-carbamates (1u and 1w) displayed improved cytotoxicities with GI50 values in the 
low-micromolar range (Table 2). A 9-O-allyl cinchonidine derivative (3d) which was 
additionally quaternized at the quinuclidine nitrogen with a bulky 9-methylanthracene 
substituent (note that single modification of this position with a 9-methylanthracene 
substituent (3a) already increases the cytotoxic activity of cinchona alkaloids slightly; see 
below and Table 4) exhibited cytotoxic activities with GI50 values in the low-micromolar 
range as well (Table 2). Furthermore, compounds with a C-9 amino group of inverted 
absolute configuration instead of the native C-9 hydroxy group (2a-c) showed slightly 
improved cytotoxic activities (~4-fold lower GI50 value; Table 2). A 9-amino-9-epi-quinidine 
derivative in which the amino group was transformed into a 3,5-bis(trifluoromethyl) 
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phenylthiourea substituent (2e) exhibited further enhanced cytotoxicity with GI50 values in 
the low- and mid-micromolar range for tumour and normal cells, respectively (Table 2). 
 
Derivatives 1u, 1w, 2e and 3d were identified as the most toxic compounds for all cancer 
cells with GI50 values < 10 µM. As the reliability of cytotoxic assays are linked to the mode 
of action of the drug and the employed test methods, we also evaluated the cytotoxic activity 
of the four compounds with the MTT cell proliferation assay. While the MTT assay gave 
higher GI50 values for 1u, 1w and 3d, the SRB assay gave higher GI50 values for 2e (Table 2). 
As both methods (SRB and MTT) gave GI50 values of the same order of magnitude (1-10 
µM), it can be concluded that the determined concentration range is the effective level of 
cytotoxicity of the four compounds. 
 
In comparison to cytarabine and doxorubicin (reference drugs), two currently used 
conventional anti-cancer drugs, the four most cytotoxic compounds 1u, 1w, 2e and 3d 
displayed lower cytotoxicities (Table 2). Based on the results obtained by the MTT assay, 
only compound 2e approximated the cytotoxic level of doxorubicin. However, a previous 
report showed that cytarabine displayed lower cytotoxic activity with GI50 values of 3-5 µM 
when determined with the SRB assay.
[22]
 Based on this, it can be assumed that the four 
compounds exhibited similar cytotoxic activity levels as compared with cytarabine. 
 
Overall, tumour cells were found to be more sensitive to all of the compounds tested than 
normal cells (Table 2). This observation indicates that cinchona alkaloid derivatives interfere 
with the replication of rapidly dividing cancer cells that are generally more susceptible to 
mitotic reagents than slow dividing normal cells. It is most likely that the compounds cause 
DNA damage that lead to cell death by apoptosis (see section 3.2). To determine the 
selectivity for the four most cytotoxic derivatives 1u, 1w, 2e and 3d, selectivity indices (SIs) 
were calculated as the ratio of the GI50 on the normal HDF cell line to the GI50 on the 
respective tumour cell line (Table 3). We calculated the SI only for 1u, 1w, 2e and 3d 
because these four compounds fulfil the pre-screen criterion for new anti-cancer agents 
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according to the National Cancer Institute (predetermined threshold inhibition concentration 
of 10 µM).
[23]
 As cytotoxic compounds are usually not very selective, an SI of >3 is generally 
considered to be good.
[24,25]
 According to the results of the SRB assay, the derivatives 1u and 
2e displayed SI values that were close to or greater than 3 for the four tumour cell lines tested 
(Table 3) suggesting that both compounds could be interesting candidates for further drug 
development. Derivative 1w had SI values less than 3 for the four tumour cell lines (Table 3) 
indicating that this compound exhibited some general toxicity. The quaternary ammonium 
salt 3d had a surprisingly high SI value for the lung cancer cell line A-549 only (Table 3). 
The SI values calculated from the data of the MTT assay were generally lower. Only 2a had 
an SI value of >2 for HeLa and A-59 cells (Table 2). On the other hand, the reference drugs 
cytarabine and doxorubicin showed SI values slightly higher than 2 for five tumour cell lines 
tested. 
 
3.2 Induction of apoptosis by compounds 1u, 1w, 2e, and 3d 
Since cinchona alkaloids have been shown to be able to trigger apoptosis in cancer cells,
[5,26]
 
we were wondering whether the cytotoxic action of the four most potent derivatives was due 
to the induction of programmed cell death. The ability of compounds 1u, 1w, 2e and 3d to 
induce apoptosis was investigated with five cancer cell lines (HeLa, KB, A-549, U-87 and 
Hep-G2). Cells were treated with three different concentrations of each compound (0.1 
µg/ml, 1 µg/ml and 10 µg/ml) and fragmentation of DNA as indicator for apoptosis was 
determined using a cell death ELISA. All four compounds induced apoptosis to a similar 
extent in all five cancer cell lines (Figure 1). A significant increase in the apoptotic index was 
found for all compounds with increasing concentration indicating that the induction of 
apoptosis was dose-dependent. At the lower concentrations of 0.1 and 1 µg/ml, 3d was the 
most effective compound in inducing apoptosis with mean apoptotic indices of 1.77 and 3.92, 
respectively. At the higher concentration of 10 µg/ml, 2e proved to be the most potent 
apoptosis-inducing derivative with a mean apoptotic index of 6.97. 
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Although the underlying mechanisms of the derivatives in triggering apoptosis in cancer 
cells remains unknown, studies with their unmodified counterparts may provide some clues 
to possible modes of action. For example, cinchona alkaloids have been shown to intercalate 
into DNA which can trigger apoptosis.
[26]
 Cinchonine has been reported to induce 
programmed cell death in cancer cells through competitive binding of TRAF6 leading to 
subsequent inhibition of AKT and TAK1 signalling pathways.
[5]
 Quinine was found to trigger 
its apoptotic effect through the inhibition of the NF-κB signalling pathway via reduction of 
Bcl2 and mutant p53 and simultaneous up-regulation of caspase-3 and Bax.
[27]
 
 
3.3 Trypanotoxicity of cinchona alkaloid derivatives 
Since compounds that display anti-cancer activity often also exhibit trypanocidal activity,
[28]
 
we tested the cinchona alkaloid derivatives for their activity to inhibit the growth of 
bloodstream forms of T. b. brucei as well. The unmodified cinchona alkaloids 1a-d (quinine, 
quinidine, cinchonine and cinchonidine, respectively) showed similar antitrypanosomal 
activities with GI50 values in the low to mid micromolar range and MIC values of 10 to 100 
µM as previously reported (Table 4).
[6,29]
 Most derivatives displayed similar or lower 
trypanocidal activity than their unmodified counterparts (Table 4). Exceptions were 
compounds 1n, 1o and 2a, which showed no activity against trypanosomes with MIC and 
GI50 values >100 µM, and compounds 2e and 3d, which exhibited enhanced trypanocidal 
activity with MIC values below 10 µM and GI50 values in the sub-micromolar range (Table 
4). When compared with the MIC value and the GI50 value of suramin (Table 4; reference 
drug), one of the drugs used in the treatment of sleeping sickness, compounds 2e and 3d 
were, however, about 10 times less trypanocidal. Interestingly, these two compounds were 
among the four derivatives that were highly active against the six cancer cell lines (see Table 
2). The selectivity of the cinchona alkaloid derivatives was determined with human 
leukaemia HL-60 cells because their sensitivity for approved trypanocides is well 
established.
[6,30]
 Most compounds including the unmodified cinchona alkaloids showed no 
cytotoxicity against HL-60 cells (Table 4). Only compounds 1s, 1u, 1v, 1w, 2e, 3a and 3d 
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displayed different levels of cytotoxic activity against the leukaemia cells with GI50 values in 
the mid- to low-micromolar range. As the most trypanocidal compounds 2e and 3d were also 
quite cytotoxic for HL-60 cells, their SI were only moderate (just below 10) (Table 4). For 
comparison, drugs used for treatment of sleeping sickness have much higher SIs.
[6,30]
 For 
example, the reference drug suramin displayed no cytotoxicity towards HL-60 cell and 
accordingly the MIC and GI50 ratios of this trypanocide were >1000 and >2941, respectively 
(Table 4). However, as HL-60 cells are cancer cells, the selectivity of the two compounds 
may be overestimated. In fact, the most trypanocidal compound 2e was 1.5 to 6 times less 
cytotoxic towards non-malignant HDF cells than towards HL-60 cells (Table 2 and 4). Based 
on this, the selectivity index of compound 2e would be 15-60. Hence, derivative 2e almost 
fulfils the activity criteria for drug candidates for African trypanosomiaisis (GI50 < 1 μM; SI 
> 100).
[33]
 
 
4 CONCLUSION 
This investigation has shown that naturally occurring cinchona alkaloids can be considered as 
a source for an easy construction of derivatives with increased cytotoxic and trypanocidal 
activity. Of the four compounds (1u, 1w, 2e and 3d) that displayed remarkable cytotoxicity, 
two derivatives (2e and 3d) exhibited also strong antitrypanosomal activity. The common 
structural feature of all four compounds was the replacement of their C-9 hydroxy group to 
either O-carbamates (1u and 1w), to thiourea (2e), or to O-allyl ether (3d). Thus, it seems that 
appropriate modification of the C-9 hydroxy group is crucial for improving the anti-
proliferative activity of cinchona alkaloid derivatives. In addition, a particular 
stereochemistry of the alkaloid moiety is not a prerequisite for the activity as three (1u, 1w 
and 3d) out of the four compounds had 8S,9R configuration (as in quinine or cinchonidine) 
but the 9-epimeric compound 2e with 8S,9S configuration displayed also high potency. Both 
9-O-protected quaternary salts and 9-thiourea derivatives turned out to be the promising 
candidates for further activity optimization. Studies in this area are in progress and will be 
presented in due course. 
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FIGURE LEGENDS 
Figure 1 Induction of apoptosis in cancer cells by cinchona alkaloid derivatives 1u (A), 1w 
(B), 2e (C) and 3d (D). Five cancer cell lines (KB, HeLa, A-549, Hep-G2 and U-87) were 
treated with the test compounds at concentrations of 0.1, 1 and 10 µg/ml for 4 h. Apoptosis 
was determined with a cell death ELISA. The apoptotic index refers to the ratio of 
nucleosome enrichment in treated cells to untreated (control) cells. Data shown are means ± 
SD from three independent experiments. 
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N O T E S 
a
Originally, the KB cell line was derived from an epidermal carcinoma of the mouth of an 
adult male Caucasian, but was subsequently contaminated with HeLa cells. As KB cells are 
indistinguishable from HeLa cells by DNA fingerprinting, KB cells should be considered as 
derived from HeLa cells.  
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TABLE 1 Chemical structure of cinchona alkaloids (1a-e) and their derivatives (1f-w, 2a-e, 
3a-d) 
 
 
Compound 
Configuration 
at C-8 and C-9 R1 R2 R3 X
-
 
Unmodified cinchona alkaloids 
1a 8S,9R OMe OH vinyl - 
1b 8R,9S OMe OH vinyl - 
1c 8R,9S H OH vinyl - 
1d 8S,9R H OH vinyl - 
1e 8R,9R OMe OH vinyl - 
Modification of vinyl group 
1f 8S,9R OMe OH ethyl - 
1g 8R,9S OMe OH ethyl - 
1h 8R,9R OMe OH ethyl - 
1i 8S,9R OH OH ethyl - 
1j 8R,9S OH OH ethyl - 
1k 8R,9S H OH ethyl - 
1l 8S,9R OMe OH ethynyl - 
1m 8R,9S OMe OH ethynyl - 
1n 8R,9S H OH COOH - 
1o 8S,9R H OH COOH - 
1p 8S,9R H OH COOEt - 
Modification of 9-hydroxy group 
1q 8R OMe H ethyl - 
1r 8S,9R OMe OAc vinyl - 
 
1a-w, 2e 2a-d 3a-d
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1s 8S,9R OMe OBz vinyl - 
1t 8S,9R OMe 
 
vinyl - 
1u 8S,9R OMe 
 
vinyl - 
1v 8S,9R OMe 
 
vinyl - 
1w 8S,9R OMe 
 
vinyl - 
9-Amino-9-epi-alkaloids and their derivatives 
2a 8S,9S OMe - vinyl - 
2b 8R,9R OMe - vinyl - 
2c 8S,9S H - vinyl - 
2d 8S,9S OMe - ethynyl - 
2e 8R,9R OMe 
 
vinyl - 
Quaternary ammonium salt derivatives 
3a 8S,9R OMe OH 
 
Cl
-
 
3b 8S,9R OMe OH 
 
Br
-
 
3c 8S,9R OMe OH 
 
Br
-
 
3d 8S,9R H 
 
 
Br
-
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TABLE 2 In vitro activity of cinchona alkaloid derivatives against tumour and normal cells
a
 
 
  Tumour cells  Normal cells 
Compound  KB HeLa MCF-7 A-549 Hep-G2 U-87  HDF CHO 
Unmodified cinchona alkaloids 
1a  55.5±0.1 56.4±1.2 55.5±0.1 n.d.
b
 n.d. n.d.  160±1 n.d. 
1b  38.3±0.3 37.0±0.2 36.4±0.1 n.d. n.d. n.d.  151±1 n.d. 
1c  109±1 155±1 129±1 n.d. n.d. n.d.  397±1 n.d. 
1d  67.6±0.1 65.9±0.3 96.8±0.7 n.d. n.d. n.d.  236±1 n.d. 
1e  67.2±0.5 64.7±0.2 64.7±1.4 67.5±0.1 n.d. n.d.  120±1 111±3 
Modification of vinyl group 
1f  83.6±0.1 82.7±0.6 82.7±1.0 66.8±0.1 n.d. n.d.  123±1 89.1±0.1 
1g  67.7±0.9 69.8±0.2 75.1±1.7 55.8±0.1 n.d. n.d.  184±1 211±2 
1h  59.4±0.5 58.5±1.2 58.2±0.4 58.2±0.9 n.d. n.d.  85.8±0.1 65.9±1.5 
1i  76.8±0.2 73.3±0.2 70.7±0.1 52.5±0.9 n.d. n.d.  89.6±0.4 102±1 
1j  40.3±0.4 38.4±1.6 38.4±0.2 25.9±1.1 n.d. n.d.  61.8±0.3 54.4±1.0 
1k  229±1 169±1 194±1 173±2 n.d. n.d.  273±1 293±1 
1l  52.4±0.2 49.6±2.6 49.6±0.4 n.d. n.d. n.d.  436±1 n.d. 
1m  149±1 140±1 153±1 n.d. n.d. n.d.  270±1 n.d. 
1n  86.4±0.1 92.8±2.6 92.8±0.5 75.6±0.2 n.d. n.d.  101±4 102±1 
1o  122±1 102±1 112±1 112±1 n.d. n.d.  193±1 195±1 
1p  55.8±0.8 56.7±0.3 55.8±0.1 32.3±0.1 n.d. n.d.  61.7±1.8 76.7±0.1 
Modification of 9-hydroxy group 
1q  145±1 158±1 137±1 110±1 n.d. n.d.  284±1 263±1 
1r  60.3±1.7 73.7±1.1 59.8±0.2 35.2±0.1 n.d. n.d.  131±1 114±1 
1s  94.7±1.5 105±1 107±1 74.9±0.4 n.d. n.d.  145±1 145±1 
1t  73.2±0.8 72.2±0.1 59.5±1.8 50.5±0.3 n.d. n.d.  89.7±0.1 89.7±0.1 
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1u  3.98±0.02 3.79±2.07 3.22±0.16 0.95±0.03 n.d. n.d.  11.6±0.1 11.4±0.4 
1u (MTT)  5.65±0.06 5.80±2.03 n.d 5.39±0.23 4.06±0.21 5.20±0.63  7.36±0.17 n.d. 
1w  3.11±0.12 1.90±0.05 2.24±0.01 2.24±0.31 n.d. n.d.  4.31±0.05 4.83±0.91 
1w (MTT)  7.44±0.07 7.06±0.02 n.d. 7.56±0.12 7.11±0.03 8.47±0.76  10.5±0.7 n.d. 
9-Amino-9-epi-alkaloids and their derivatives 
2a  15.7±1.0 13.9±0.4 15.5±1.6 13.2±0.5 n.d. n.d.  25.4±0.1 27.1±0.8 
2b  18.5±0.4 18.5±0.9 18.5±0.8 16.9±0.4 n.d. n.d.  38.1±0.1 41.6±0.1 
2c  15.1±0.3 14.9±0.5 13.2±0.1 12.4±0.1 n.d. n.d.  21.1±2.6 21.1±0.9 
2e  4.88±0.6 2.86±0.23 3.20±0.03 2.86±0.03 n.d. n.d.  19.3±0.8 18.5±0.1 
2e (MTT)  2.91±0.07 1.79±0.05 n.d. 1.98±1.40 3.13±0.25 1.96±1.19  4.76±0.13 n.d. 
Quaternary ammonium salt derivatives 
3d  1.32±0.02 1.32±0.08 1.32±0.01 0.20±0.11 n.d. n.d.  2.64±0.15 1.82±0.49 
3d (MTT)  6.62±1.27 6.92±0.10 n.d. 8.01±0.03 7.61±0.02 6.89±0.81  11.8±0.1 n.d. 
Reference drugs 
cytarabine (MTT)  0.62±0.04 0.66±0.12 n.d. 0.45±0.70 0.53±0.25 0.78±0.37  1.32±0.49 n.d. 
doxorubicin (MTT)  1.25±0.13 1.14±0.29 n.d. 1.31±0.02 1.34±0.24 1.42±0.04  2.93±0.09 n.d. 
a
The cytotoxic activity of test compounds was determined using the SRB assay or the MTT assay (indicated). Results are mean values of three 
independent experiments and expressed as GI50 values ± SD in µM. KB, human cervix carcinoma derived from HeLa cells; HeLa, human cervix 
carcinoma; MCF-7, human breast cancer; A-549, human lung cancer; HepG2, human hepatocyte carcinoma; U-87, human glioblastoma: HDF, 
human dermal fibroblast; CHO, Chinese hamster ovary cells. 
b
n.d., not determined. 
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TABLE 3 Selectivity indices for the most active compounds (with GI50 values <10 µM) 
 
  SI
a
 
Compound  KB HeLa MCF-7 A-549 Hep-G2 U-87 
1u  2.9 3.1 3.6 12.2 n.d.
b
 n.d. 
1u (MTT)  1.3 1.3 n.d. 1.4 1.8 1.4 
1w  1.4 2.3 1.9 1.9 n.d. n.d. 
1w (MTT)  1.4 1.5 n.d. 1.4 1.5 1.2 
2e  4.0 6.7 6.0 6.7 n.d. n.d. 
2e (MTT)  1.6 2.8 n.d. 2.4 1.5 2.4 
3d  2.0 2.0 2.0 13.2 n.d. n.d. 
3d (MTT)  1.8 1.7 n.d. 1.5 1.6 1.7 
cytarabine (MTT)  2.1 2.0 n.d. 2.9 2.5 1.7 
doxorubicin (MTT)  2.3 2.6 n.d. 2.2 2.2 2.1 
a
The selectivity index (SI) is defined as the ratio of the GI50 on the normal cell line HDF to 
the GI50 on the respective cancer cell line and were calculated from GI50 values shown in 
Table 1. An SI >1.0 indicates that the compound has a greater activity against tumour cells 
than against normal cells. 
b
n.d., not determined. 
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TABLE 4 In vitro activity of cinchona alkaloid derivatives against T. b. brucei and HL-60 
cells 
 
  T. b. brucei  HL-60 cells  Selectivity 
Compound  MIC
a
 GI50
b
  MIC
a
 GI50
b
  
MIC 
ratio
c
 
GI50 
ratio
d
 
Unmodified cinchona alkaloids 
1a  10 3.26±0.32  >100 >100  >10 >30 
1b  10 2.62±0.26  >100 >100  >10 >38 
1c  10 3.61±0.29  >100 >100  >10 >27 
1d  100 23.8±10.1  >100 >100  >1 >4.2 
1e  >100 44.1±9.1  >100 >100  n.a.
e
 >2.2 
Modification of vinyl group 
1f  10-100 (40) 3.75±0.93  >100 >100  >1-10 >26 
1g  10 2.72±0.35  >100 >100  >10 >36 
1h  100 24.8±3.2  >100 >100  >1 >4.0 
1i  100 26.2±4.7  >100 >100  >1 >3.8 
1j  10 5.58±3.05  >100 >100  >10 >17 
1k  10-100 (40) 4.98±0.88  >100 >100  >1-10 >20 
1l  100 22.3±6.2  >100 >100  >1 >4.4 
1m  100 29.4±13.6  >100 >100  >1 >3.4 
1n  >100 >100  >100 >100  n.a. n.a. 
1o  >100 >100  >100 >100  n.a. n.a. 
1p  100 34.5±6.4  >100 >100  >1 >2.8 
Modification of 9-hydroxy group 
1q  100 27.2±6.4  >100 >100  >1 >3.6 
1r  100 16.5±8.7  >100 >100  >1 >6.0 
1s  10-100 (40) 3.44±0.72  100 35.7±2.6  1-10 10.4 
1t  100 22.2±7.7  >100 >100  >1 >4.5 
1u  100 26.7±4.7  100 37.6±1.7  1 1.4 
1v  10 3.24±1.44  100 35.5±1.2  10 11.0 
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1w  10 3.09±0.42  100 35.3±1.7  10 11.4 
9-Amino-9-epi-alkaloids and their derivatives 
2a  >100 >100  >100 >100  n.a. n.a. 
2b  100 30.6±5.0  >100 >100  >1 >3.2 
2c  100 26.5±6.8  >100 >100  >1 >3.7 
2d  >100 48.1±21.6  >100 >100  n.a. >2.0 
2e  1 0.33±0.04  10 3.16±0.10  10 9.6 
Quaternary ammonium salt derivatives 
3a  10 3.22±0.22  100 31.9±1.2  10 9.9 
3b  100 38.5±1.9  >100 >100  >1 >2.5 
3c  100 43.5±5.2  >100 >100  >1 >2.2 
3d  1-10 (7) 0.41±0.17  10 3.97±0.43  1-10 9.7 
Reference drug 
suramin  0.1 0.034±0.002  >100 >100  >1000 >2941 
a
MIC values are expressed in µM. In case that not all three experiments gave the same MIC 
value, a range from the lowest to the highest MIC values observed is instead provided with 
the average MIC value in parenthesis. 
b
GI50 values are expressed as mean values ± SD in µM. 
c
Defined as MIC(HL-60)/MIC(T. b. brucei). 
d
Defined as GI50(HL-60)/GI50(T. b. brucei). 
e
n.a., not assignable (since values for both HL-60 cell and T. b. brucei are >100 µM). 
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